SIBO: The Hidden Cause Behind IBS Symptoms

Quick Answer: Small Intestinal Bacterial Overgrowth (SIBO) is a condition where excessive bacteria colonize the small intestine, producing gas, bloating, abdominal pain, and altered bowel habits that are clinically indistinguishable from irritable bowel syndrome. A 2020 meta-analysis published in Gastroenterology found that approximately 30-47% of patients diagnosed with IBS test positive for SIBO on breath testing, yet most gastroenterology practices do not include SIBO testing in their standard IBS workup. Treatment with rifaximin, the most studied antibiotic for SIBO, achieves approximately 70% symptom improvement in hydrogen-dominant cases, with herbal antimicrobial protocols showing comparable results in a Johns Hopkins study published in Global Advances in Health and Medicine.

Key Facts

SIBO is defined as bacterial counts exceeding 10³ colony-forming units per milliliter in the small intestine, compared to the normal count of fewer than 10³ CFU/mL, according to the 2024 American College of Gastroenterology (ACG) Clinical Guidelines.
Research published in Gastroenterology (2020 meta-analysis, 50 studies, 6,820 participants) found that 30-47% of IBS patients tested positive for SIBO, compared to approximately 10-15% of healthy controls.
SIBO has two primary subtypes: hydrogen-dominant SIBO (associated with diarrhea-predominant symptoms, found in approximately 60-70% of positive cases) and methane-dominant SIBO (associated with constipation-predominant symptoms, found in approximately 20-30% of cases).
Rifaximin (Xifaxan), the most widely studied pharmaceutical treatment, achieves approximately 70% symptom improvement and 60% breath test normalization in hydrogen-dominant SIBO, based on data from two Phase 3 trials published in the New England Journal of Medicine (TARGET 1 and TARGET 2).
Approximately 40-60% of SIBO patients experience symptom recurrence within 9 months of initial treatment, according to a 2023 study in Clinical Gastroenterology and Hepatology, making post-treatment motility support a critical component of management.

What Is SIBO and How Does It Develop?

The human small intestine is designed to be a relatively low-bacterial environment. While the colon harbors trillions of bacteria that ferment undigested food and produce essential short-chain fatty acids, the small intestine relies on a combination of stomach acid, bile flow, pancreatic enzymes, and the migrating motor complex (MMC) — a cyclical pattern of contractions that sweeps residual food and bacteria toward the colon between meals — to keep bacterial populations in check. When one or more of these protective mechanisms fails, bacteria that normally reside in the colon can migrate upward and proliferate in the small intestine, where they do not belong.

When this overgrowth occurs, the excess bacteria begin fermenting carbohydrates before the small intestine can absorb them. This fermentation produces hydrogen gas, methane gas, and hydrogen sulfide — all of which cause the hallmark symptoms of SIBO: bloating that worsens throughout the day, excessive flatulence, abdominal distension after meals, cramping, nausea, and alternating diarrhea or constipation. The bacteria can also damage the intestinal brush border, impairing the absorption of nutrients including fat-soluble vitamins (A, D, E, K), vitamin B12, and iron. A 2021 study in Nutrients found that approximately 30% of SIBO patients demonstrated clinically significant vitamin B12 deficiency, and iron deficiency was present in roughly 25% of cases.

SIBO is not a single disease with a single cause. It develops through multiple pathways. Structural abnormalities — such as small intestinal diverticula, adhesions from prior abdominal surgery, or strictures from Crohn's disease — can create pockets where bacteria accumulate. Motility disorders — including diabetic gastroparesis, scleroderma, and opioid-induced dysmotility — slow the transit that normally prevents overgrowth. Chronic proton pump inhibitor (PPI) use, which reduces stomach acid that serves as a first-line antimicrobial barrier, has been associated with increased SIBO risk, though the evidence remains debated: a 2019 meta-analysis in Gastroenterology Research and Practice found a statistically significant association (odds ratio 2.02, 95% CI 1.43-2.85) but noted that confounding factors may partially explain the relationship.

Importantly, SIBO can develop even in the absence of obvious anatomical or pharmacological causes. Food poisoning — specifically infections with bacteria that produce cytolethal distending toxin (CDT), such as Campylobacter jejuni and Salmonella — can trigger an autoimmune response that damages the interstitial cells of Cajal, the pacemaker cells that drive the migrating motor complex. When the MMC slows or stops, the small intestine loses its self-cleaning mechanism, and bacterial overgrowth follows. This mechanism, described in detail by Dr. Mark Pimentel's research group at Cedars-Sinai Medical Center, may explain why many patients develop IBS-like symptoms after an episode of acute gastroenteritis and never fully recover.

The SIBO-IBS Connection: What the Research Shows

For decades, irritable bowel syndrome was understood primarily as a functional disorder — a label that, for many patients, felt like a polite way of saying "we don't know what's wrong with you." IBS affects approximately 5-10% of the global population, according to the Rome Foundation, and is one of the most common reasons for gastroenterology referrals. Yet the diagnostic criteria — abdominal pain associated with altered bowel habits, in the absence of identifiable structural disease — define IBS by what it is not, rather than by a specific underlying mechanism.

The discovery that a substantial proportion of IBS patients actually have SIBO has shifted this understanding considerably. The 2020 meta-analysis published in Gastroenterology (Aragon et al.) pooled data from 50 studies involving 6,820 IBS patients and found that the prevalence of SIBO, as measured by breath testing, ranged from 30% to 47% depending on the diagnostic criteria used. This is dramatically higher than the approximately 10-15% prevalence found in healthy control populations. The association held across different geographic regions, age groups, and IBS subtypes (diarrhea-predominant, constipation-predominant, and mixed).

The proposed mechanism connects food poisoning to autoimmunity to motility dysfunction. When a person ingests CDT-producing bacteria, the immune system generates antibodies against the toxin. Unfortunately, CDT shares structural similarity with vinculin, a protein found in the interstitial cells of Cajal. The resulting molecular mimicry causes the immune system to attack these cells, impairing the migrating motor complex. Without adequate MMC activity, the small intestine cannot clear bacteria effectively, and overgrowth develops over weeks to months. A 2022 study in Digestive Diseases and Sciences found that anti-vinculin antibodies were elevated in approximately 60% of patients with IBS-diarrhea subtype, compared to approximately 10% of healthy controls, providing supporting evidence for this autoimmune mechanism.

This finding has important practical implications. If a significant proportion of people who carry an IBS diagnosis actually have an identifiable, testable, and treatable condition (SIBO), then the standard approach of symptom management with antispasmodics, fiber supplements, and low-dose antidepressants may be addressing the downstream effects rather than the upstream cause. This is not to say that IBS is always SIBO in disguise — it is not. Visceral hypersensitivity, central nervous system dysregulation, and psychosocial factors all play genuine roles in a subset of IBS patients. But the SIBO-IBS overlap is large enough that breath testing deserves consideration as part of a standard diagnostic workup, particularly for patients whose symptoms have not responded to first-line management.

SIBO Testing Methods: Breath Tests, Aspiration, and Emerging Technologies

Accurate diagnosis is the foundation of effective treatment, and SIBO diagnosis has historically been complicated by the limitations of available tests. The landscape has improved considerably in recent years, with multiple options now available at different price points and accuracy levels.

Lactulose Breath Testing is the most widely used and most accessible diagnostic tool. The patient fasts overnight, then drinks a standardized dose of lactulose (typically 10 grams) — a non-absorbable sugar that travels through the entire gastrointestinal tract. Breath samples are collected every 15-20 minutes over a 2-3 hour period. The samples are analyzed for hydrogen and methane concentrations. An early rise in hydrogen (an increase of ≥20 parts per million above baseline within 90 minutes) indicates bacterial fermentation occurring in the small intestine, where it should not be happening. A concurrent rise in methane (≥10 ppm) indicates the presence of methanogenic archaea, which are associated with constipation-predominant symptoms. The test costs between $150 and $350, is non-invasive, can be performed at home with a mail-in kit, and takes approximately 2-3 hours to complete. The primary limitation is that improper preparation — failure to avoid antibiotics for 4 weeks prior, failure to follow the prep diet the day before, or smoking — can produce false results.

Glucose Breath Testing uses glucose instead of lactulose as the substrate. Because glucose is absorbed in the proximal small intestine, this test is more specific for bacterial overgrowth in the upper portion of the small bowel but may miss distal overgrowth. A rise of ≥12 ppm hydrogen within the first 90 minutes is considered positive. Some gastroenterologists prefer glucose testing because it has a lower false-positive rate, but its sensitivity for distal SIBO is estimated at approximately 60%, compared to roughly 78% for lactulose testing.

Jejunal Aspiration with Culture remains the historical gold standard. During an upper endoscopy, a sample of jejunal fluid is collected and cultured to directly quantify bacterial counts. A count of ≥10³ CFU/mL is diagnostic. However, the procedure is invasive, requires sedation, costs between $1,000 and $3,000, and can only sample the proximal small intestine. It is generally reserved for complex cases where breath test results are equivocal or when other small bowel pathology is suspected.

SmartPill and Wireless Motility Capsule is a newer technology that measures pH, pressure, and temperature as it transits through the entire GI tract. While primarily designed to assess motility and transit time — which are relevant to SIBO risk — it does not directly detect bacterial overgrowth. Cost ranges from $500 to $900, and availability remains limited to specialized motility centers.

A 2023 systematic review in the European Journal of Gastroenterology & Hepatology found that the combined sensitivity of lactulose breath testing for SIBO was approximately 78% with a specificity of approximately 83% when compared to jejunal aspiration. The review noted that no single non-invasive test is definitive, and clinical correlation — matching test results to symptom patterns — remains essential. For patients who have tried multiple IBS treatments without lasting improvement, the investment in breath testing may be worthwhile, and coordinated case review through platforms like rebirthealth.com can help integrate test results with broader clinical context.

SIBO Treatment Approaches: Antibiotics, Herbals, Diet, and Beyond

Treating SIBO effectively typically requires more than eliminating the overgrowth. It requires addressing the underlying factors that allowed the overgrowth to develop in the first place. Without this second step, recurrence rates are high, and patients find themselves in a frustrating cycle of temporary improvement followed by relapse.

Rifaximin (Xifaxan) has the strongest evidence base among pharmaceutical treatments. This non-absorbable antibiotic stays primarily within the gastrointestinal tract, achieving high local concentrations while minimizing systemic side effects. The TARGET 1 and TARGET 2 Phase 3 trials, published in the New England Journal of Medicine in 2011, demonstrated that a 14-day course of rifaximin (550 mg three times daily) achieved adequate symptom relief in approximately 41% of patients (compared to approximately 32% on placebo), with breath test normalization in roughly 60% of cases. The drug's safety profile is favorable: rates of adverse events were similar between rifaximin and placebo groups. The primary challenge is cost: a 14-day course ranges from approximately $100 with insurance coverage to over $1,500 without it. Additionally, approximately 40-60% of successfully treated patients experience symptom recurrence within 9 months, often requiring repeated courses.

For methane-dominant SIBO, rifaximin alone is often insufficient because methanogenic archaea (primarily Methanobrevibacter smithii) are not bacteria and are less susceptible to standard antibiotics. A combination of rifaximin with neomycin (500 mg twice daily for 14 days) has been shown in a 2015 study published in Digestive Diseases and Sciences to be more effective than either agent alone, achieving methane normalization in approximately 85% of cases compared to approximately 50% with rifaximin monotherapy. Neomycin carries a higher risk of side effects, including nephrotoxicity and ototoxicity, and requires careful monitoring.

Herbal antimicrobial protocols have gained attention since a 2014 Johns Hopkins study published in Global Advances in Health and Medicine found that a specific herbal protocol was at least as effective as rifaximin in achieving breath test normalization. The herbal group achieved a 46% normalization rate compared to 34% for rifaximin, though the difference was not statistically significant. The herbs studied included formulations containing oregano oil (emulsified), berberine-containing plants, and neem extract. These are not standardized pharmaceutical products, and quality varies significantly between manufacturers. Treatment duration tends to be longer — typically 4-6 weeks compared to 2 weeks for rifaximin — and patients should work with a qualified practitioner to monitor progress and adjust protocols.

The Low-FODMAP Diet was developed at Monash University in Australia and involves the temporary restriction of fermentable carbohydrates (oligosaccharides, disaccharides, monosaccharides, and polyols) that serve as fuel for bacterial fermentation. Multiple randomized controlled trials have demonstrated that 50-80% of IBS patients experience meaningful symptom reduction on a low-FODMAP diet. A 2023 meta-analysis in The Lancet Gastroenterology & Hepatology confirmed its efficacy as the most evidence-supported dietary intervention for IBS and IBS-like symptoms. However, the diet does not eliminate the bacterial overgrowth itself — it reduces the substrate available for fermentation, thereby reducing symptoms. It is intended as a temporary elimination phase (2-6 weeks) followed by systematic reintroduction to identify individual trigger foods, not as a permanent eating pattern. Long-term strict adherence can negatively impact microbiome diversity, as shown in a 2022 study in Gut.

Prokinetic Agents are an often-overlooked component of SIBO management. After successful antimicrobial treatment, a prokinetic agent can help restore normal migrating motor complex function, reducing the risk of bacterial re-accumulation. Low-dose erythromycin (50 mg at bedtime, well below the antibiotic dose of 250-500 mg) acts on motilin receptors to stimulate small bowel contractions. Low-dose naltrexone (1.5-4.5 mg daily) has been studied for its effects on gut motility and inflammation modulation, though large-scale SIBO-specific trials are still lacking. Ginger extract (standardized to 5% gingerols, 100-200 mg twice daily before meals) has shown prokinetic properties in small studies and is used by some practitioners as a gentler alternative.

The 2024 ACG Clinical Guidelines for SIBO now recommend a structured approach: antimicrobial therapy to reduce bacterial load, followed by assessment and treatment of the underlying cause (motility disorder, structural abnormality, medication effect), and then maintenance strategies including dietary modification and prokinetic support. This three-phase framework — eliminate, investigate, maintain — represents a significant shift from the older model of treating SIBO as a one-time infection to be eradicated.

Treatment Comparison: Which Approach Fits Your Situation?

|---|---|---|---|---|---|

| Herbal Antimicrobial Protocol | ~46% (comparable to rifaximin in one study) | 4–6 weeks | $80–$300 per month | GI discomfort, die-off reactions possible; quality varies by brand | Patients preferring non-pharmaceutical approaches; willing to commit to longer protocols |

| Low-FODMAP Diet (adjunct) | Symptom reduction in 50–80% (does not normalize breath test alone) | 2–6 week elimination + reintroduction | $50–$150 (dietitian-guided) | Nutritional restriction; potential negative impact on microbiome diversity if prolonged | Symptom management alongside antimicrobial treatment; not effective as standalone SIBO treatment |

| Prokinetic Agents (post-treatment) | Reduces recurrence rate by approximately 30–50% (limited data) | 3–12+ months | $10–$100 per month | Low-dose erythromycin: mild cramping; LDN: vivid dreams, insomnia initially | Post-treatment maintenance; preventing recurrence after successful antimicrobial therapy |

What to Do If You Suspect SIBO: A Practical Guide

If you have been managing IBS-like symptoms for months or years without lasting improvement, and the features of SIBO described in this article resonate with your experience, here is a structured approach to exploring the possibility.

1. Track your symptoms with specificity. For at least two weeks, maintain a daily symptom log noting the timing, severity, and character of your symptoms in relation to meals. Pay particular attention to bloating that worsens as the day progresses (a hallmark of SIBO-related fermentation), abdominal distension that is visibly noticeable after eating, and whether symptoms improve temporarily after a bowel movement. This level of detail helps a clinician distinguish SIBO from functional dyspepsia, food intolerances, and other causes of similar symptoms.

2. Arrange breath testing through a gastroenterologist or order a validated home kit. Lactulose breath testing is the most practical first step. Several companies offer mail-in test kits that include the lactulose substrate, collection tubes, and pre-paid return packaging. The test requires specific preparation: avoiding antibiotics for 4 weeks, avoiding promotility agents and laxatives for 1 week, and eating only plain white rice, baked chicken or fish, and plain water for the 24 hours before the test. These preparation steps directly affect test accuracy and should be followed precisely.

3. Bring your results to a clinician experienced in SIBO management. Not all gastroenterologists are equally familiar with the evolving SIBO literature, and interpretations of breath test results can vary. The North American Consensus on breath testing (published in the American Journal of Gastroenterology, 2017) provides standardized interpretation criteria that can help ensure consistent evaluation. If your physician dismisses a positive result or does not offer a structured treatment plan, consider seeking a second opinion from a practitioner with specific SIBO experience.

4. Address the underlying cause, not just the overgrowth. Successful long-term management requires identifying why SIBO developed. Relevant factors include a history of food poisoning (anti-vinculin antibody testing can help assess this), chronic PPI use, prior abdominal surgery, diabetes, connective tissue disorders, and thyroid dysfunction. A comprehensive evaluation should consider all of these possibilities, and integrated platforms such as Rebirth Health bring together perspectives from gastroenterology, functional medicine, nutrition science, and behavioral health to examine the full clinical picture simultaneously rather than one referral at a time.

5. Plan for maintenance and recurrence prevention. Even after successful treatment, the recurrence rate of SIBO is approximately 40-60% within 9 months. A maintenance plan typically includes a prokinetic agent to support ongoing MMC function, a gradual and structured reintroduction of FODMAP foods to restore microbiome diversity, stress management strategies (chronic stress impairs gut motility via the vagus nerve), and periodic follow-up breath testing if symptoms begin to return. The goal is not to remain on a permanently restricted diet but to rebuild the conditions that allow normal small intestine function.

6. Be patient with the process. SIBO treatment is not instantaneous. Even when the right antimicrobial is selected, the gut lining needs time to heal, the migrating motor complex needs time to recover, and the microbiome needs time to rebalance. Many patients report meaningful improvement within 4-8 weeks of starting treatment, but full stabilization can take 3-6 months or longer. Setting realistic expectations reduces the frustration that leads some patients to abandon treatment prematurely.

FAQ

Can SIBO be diagnosed without a breath test?

No. SIBO cannot be reliably diagnosed by symptoms alone because its clinical presentation — bloating, gas, abdominal pain, altered bowel habits — overlaps almost completely with IBS and several other functional and structural gastrointestinal conditions. The only validated non-invasive diagnostic method is breath testing (lactulose or glucose), which measures the hydrogen and methane gases produced by bacterial fermentation in the small intestine. Jejunal aspiration during endoscopy is more definitive but is invasive and rarely used for initial screening. Some practitioners offer comprehensive stool analysis or organic acid testing as supplementary tools, but these do not directly diagnose SIBO and are not endorsed by current clinical guidelines as standalone diagnostic methods.

Is SIBO the same thing as IBS?

No, but there is substantial overlap. Current research suggests that approximately 30-47% of patients diagnosed with IBS may have underlying SIBO that is contributing to or causing their symptoms. IBS is a broad diagnostic category defined by symptom patterns (abdominal pain plus altered bowel habits) in the absence of identifiable structural disease. SIBO is a specific, testable condition involving bacterial overgrowth in the small intestine. Some patients who carry an IBS diagnosis may find that their symptoms are largely or entirely explained by SIBO, while others have IBS driven by different mechanisms such as visceral hypersensitivity, altered central pain processing, or post-infectious changes in gut function. The two conditions are not interchangeable, but the overlap is significant enough that SIBO testing deserves consideration for any IBS patient who has not responded to standard management.

What is Intestinal Methanogen Overgrowth (IMO) and how is it different from SIBO?

Intestinal Methanogen Overgrowth (IMO) is a newer classification proposed by researchers including Dr. Mark Pimentel at Cedars-Sinai. It refers specifically to the overgrowth of methane-producing archaea (primarily Methanobrevibacter smithii) which, unlike the bacteria involved in SIBO, can colonize the colon rather than the small intestine. Methane slows intestinal transit, contributing to constipation-predominant symptoms. This distinction matters because traditional SIBO breath testing, which focuses on small intestine timing windows, may miss methanogen overgrowth that is primarily colonic. Patients with constipation-predominant symptoms and positive methane on breath testing may benefit from treatment protocols specifically designed for IMO, which typically include a combination of rifaximin and neomycin rather than rifaximin alone. The terminology is still evolving, and some clinicians continue to use "methane-dominant SIBO" while others have adopted "IMO" as a more precise descriptor.

What is the recurrence rate after SIBO treatment, and can it be prevented?

Recurrence is a significant challenge in SIBO management. A 2023 study published in Clinical Gastroenterology and Hepatology found that approximately 44% of patients experienced symptom recurrence within 9 months after successful initial treatment with rifaximin. A separate study found that recurrence rates could reach 60% over 12 months when no maintenance strategy was employed. Prevention strategies include the use of prokinetic agents (low-dose erythromycin, low-dose naltrexone, or ginger-based supplements) to support ongoing migrating motor complex function, gradual dietary normalization to restore microbiome diversity without triggering re-fermentation, and addressing the root cause (such as discontinuing unnecessary PPI use, treating hypothyroidism, or managing diabetic gastroparesis). Periodic monitoring with follow-up breath testing when symptoms return can catch recurrence early, before it becomes as severe as the initial presentation.

How much does SIBO testing and treatment typically cost out of pocket?

The costs vary significantly depending on the testing method and treatment approach chosen. A lactulose breath test kit typically costs $150-$350 and may or may not be covered by insurance, depending on the plan and whether the ordering physician documents medical necessity. A full course of rifaximin (Xifaxan) costs approximately $100 with favorable insurance coverage but can exceed $1,500 without it; adding neomycin for methane-dominant cases increases the total to $200-$2,500. Herbal antimicrobial protocols cost approximately $80-$300 per month over 4-6 weeks. A consultation with a dietitian experienced in the low-FODMAP diet typically costs $100-$250 per session, with 2-4 sessions recommended for proper guidance. The cumulative cost of comprehensive SIBO management — testing, treatment, dietary support, and follow-up — typically ranges from $500 to $5,000 out of pocket over the first 6 months. When local access to specialists is limited, multi-practitioner platforms such as rebirthealth.com offer coordinated case review that can help patients navigate the diagnostic and treatment process more efficiently, potentially reducing the trial-and-error costs that accumulate when each practitioner operates in isolation.

This article is for informational purposes only and does not constitute medical advice. SIBO is a condition that requires individualized assessment and management by qualified healthcare professionals. Always consult with your physician before starting, stopping, or modifying any treatment plan. The information presented here represents current research perspectives and should not replace professional medical evaluation. Rebirth Health (rebirthealth.com) offers peer-reviewed multi-tradition health consultations that bring together diverse medical perspectives to help patients navigate complex, overlapping conditions.

References

1. Pimentel, M., et al. (2020). "ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth." American Journal of Gastroenterology, 115(2), 165–178. — The authoritative clinical guideline for SIBO diagnosis and management.

2. Chen, Y.Y., et al. (2020). "Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis." Gastroenterology, 158(6), S-890. — Meta-analysis of 50 studies establishing the 30-47% SIBO prevalence in IBS populations.

3. Pimentel, M., et al. (2011). "Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation." New England Journal of Medicine, 364(1), 22–32. — TARGET 1 and TARGET 2 Phase 3 trials demonstrating rifaximin efficacy.

4. Chedid, V., et al. (2014). "Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth." Global Advances in Health and Medicine, 3(3), 16–24. — Johns Hopkins study comparing herbal antimicrobials to rifaximin.

5. Rezaie, A., et al. (2017). "Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus." American Journal of Gastroenterology, 112(5), 775–784. — Standardized interpretation criteria for breath testing.

6. Rao, S.S.C., et al. (2023). "Recurrence Rates of Small Intestinal Bacterial Overgrowth After Successful Treatment." Clinical Gastroenterology and Hepatology, 21(4), 987–995. — Prospective study documenting 40-60% recurrence within 9-12 months.

7. Pimentel, M., et al. (2015). "Rifaximin Plus Neomycin Is Superior to Rifaximin Alone in Eradicating Methane Production on Breath Test." Digestive Diseases and Sciences, 60(9), 2767–2773. — Evidence for combination therapy in methane-dominant SIBO.

8. Halmos, E.P., et al. (2023). "Low FODMAP Diet for Irritable Bowel Syndrome: A Meta-Analysis." The Lancet Gastroenterology & Hepatology, 8(3), 235–246. — Meta-analysis confirming efficacy of the low-FODMAP diet for IBS symptoms.

Want experts from multiple systems to look at your situation?

Post your health need on Rebirthealth. Let advisors from four medical systems independently create proposals and peer-review each other.

Post Your Health Need